Temozolomide in the management of dopamine agonist-resistant prolactinomas

Background The majority of prolactinomas respond to dopamine agonist therapy, but a proportion are resistant, requiring other treatments including surgery and/or radiotherapy. Temozolomide is an oral chemotherapy agent, which has been used as a salvage therapy to treat aggressive pituitary adenomas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical endocrinology (Oxford) 2012-06, Vol.76 (6), p.877-886
Hauptverfasser:	Whitelaw, B. C., Dworakowska, D., Thomas, N. W., Barazi, S., Riordan-Eva, P., King, A. P., Hampton, T., Landau, D. B., Lipscomb, D., Buchanan, C. R., Gilbert, J. A., Aylwin, S. J. B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Biological and medical sciences Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Dopamine Agonists - therapeutic use Drug Resistance, Neoplasm - drug effects Endocrinopathies Fundamental and applied biological sciences. Psychology Humans Hypothalamus. Hypophysis. Epiphysis (diseases) Male Medical sciences Non tumoral diseases. Target tissue resistance. Benign neoplasms Prolactinoma - drug therapy Temozolomide Vertebrates: endocrinology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!